Latest Conference Articles

Most Americans have never heard of hereditary transthyretin amyloidosis (hATTR), which speaks to its very low incidence rate in the population.

The oncology drug pipeline has experienced rapid growth over the past decade, driven by innovation in cell therapies, immunotherapy, and precision medicine, according to a specialty pipeline update presentation at the Asembia Specialty Pharmacy Summit 2019.

Co-pay accumulator programs are the latest cost management initiative resulting from the constant push and pull between payers, pharmacy benefit managers, and manufacturers to reduce drug spend.

Treatment for inflammatory bowel disease has the best outcomes when patients partner with their medical teams.

Why health system specialty pharmacies are uniquely positioned to provide valuable data and superior care to the patients they serve.

The specialty lite platform leverages the current infrastructure of specialty pharmacies with efficient services and emerging technological solutions that focus on ensuring prescription fulfillment with economic feasibility.

Experts emphasized the need for clinicians to use every available tool when patients need PCSK9 inhibitors but face access barriers.

During a session on Monday at Asembia’s Specialty Pharmacy Summit 2019, experts discussed specialty pharmacy’s potential to improve outcomes for patients with pulmonary arterial hypertension.

Diagnostic delay tends to be a challenge for patients with hereditary angioedema, a rare but serious condition affecting 1 in 50,000 individuals.

This new offering provides an end-to-end digital prescription process with nationwide access through more than 25,000 retail pharmacies.

Check back daily for our coverage of the Asembia Specialty Pharmacy Summit this week.

What considerations should pharmacists keep in mind when treating patients with chronic lymphocytic leukemia?

Bernard Marini, PharmD, BCOP, gives an overview of selecting the most effective, safest, and most cost-effective acute myeloid leukemia treatments for patients.

The high cost of targeted treatments for acute myeloid leukemia has made it difficult for patients to access these therapies.

Lisa Holle, PharmD, BCOP, FHOPA, associate clinical professor at the University of Connecticut discusses key trials in prostate cancer research.

Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute, discussed the recent updates to the American Cancer Society's screening guidelines for colorectal cancer.

Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, provides an overview of the evolving treatment paradigm for chronic lymphocytic leukemia.

Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, discusses the importance of the pharmacist's role in the management of chronic lymphocytic leukemia treatments.

Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute, explains how pharmacists can counsel patients about risk factors for colorectal cancer and reduction strategies.

Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute, discussed emerging trends in oncology care.

In this clip, Bernard Marini, PharmD, BCOP, inpatient hematology specialist at the University of Michigan, discusses how IDH inhibitors like ivosidenib and enasidenib fit into the treatment landscape for patients with relapsed or refractory acute myeloid leukemia.

Lisa Holle, PharmD, BCOP, FHOPA, associate clinical professor at the University of Connecticut, explains which patient populations would best benefit from either apalutamide versus enzalutamide in the treatment of non-metastatic prostate cancer.

Updated clinical practice guidelines from the National Comprehensive Cancer Network (NCCN) review patient selection for the use of agents such as ibrutinib for the treatment of chronic lymphocytic leukemia.

Each year, the American Pharmacists Association presents this award awarded to a professional who goes above and beyond the call of duty.

Pharmacists work in complex settings, with some community pharmacists being required to stand for up to 12 hours at a time, skip lunch breaks, or avoid bathroom breaks.

Through overdose risk reduction education, proper medication management, and providing naloxone rescue kits to the community, pharmacists can play a vital role in helping fight the opioid epidemic

Suicide rates have risen in nearly every state since 1999.

Attendees of a session called "The Community Pharmacist's Transgender Toolkit" got valuable tips from a third-year pharmacy student at the University of Washington.